[1] LI P M， ZHANG X L， TANG K， et al. Determination of mycophcnolic acid concentration in human plasma and its application to therapeutic drug monitoring in renal transplantation patient[J]. Chin Pharm J(中国药学杂志)，2007，42(19)：1490-1493.
[2] TROPPMANN C， PAPALOIS B E， CHIOU A， et al. Incidence， complications， treatment， and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era[J]. J Am Coll Surg， 1995， 180(4)：433-443.
[3] CHEN K J， CHEN C H， CHENG C H， et al. Risk factors for peptic ulcer disease in renal transplant patient-11 years of experience from a single center[J]. Clin Nephrol， 2004，62(1)：14-20.
[4] SUWELACK B， GABRIELS G， VOLMER S， et al. Resolution of severe MMF related gastrointestinal adverse events following conversion to entericcoated mycophenolate sodium[J]. Transplantation， 2005，79(8)：987-988.
[5] ALTOMARE J F， SMITH R E， POTDAR S， et al. Delayed gastric ulcer healing associated with sirolimus[J]. Transplantation， 2006， 82(3)：437-438.
[6] STAATZ C E， TETT S E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin Pharmacokinet， 2007， 46(1)：13-58.
[7] KIBERD BA， WROBEL M， DANDAVINO R， et al. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation： evidence from the CLEAR study[J]. Ther Drug Monit， 2011 Feb;33(1)：120-123.
[8] BULLINGHAM R， SHAH J， GOLDBLUM R， et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients[J]. Br J Clin Pharmacol， 1996，41(6)：513-516.
[9] KOFLER S， DEUTSCH M-A， BIGDELI AK， et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients[J]. J Heart Lung Transplant，2009，28(6)：605-611.
[10] KOFLER S， SHVETS N， BIGDELI AK， et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients—a prospective case-controlled study[J]. Am J Transplant，2009，9(7)：1650-1656.
[11] RUPPRECHT K， SCHMIDT C， RASPE′ A， et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers[J]. J Clin Pharmacol，2009，49(10)：1196-1201.
[12] MIURA M， SATOH S， INOUE K， et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation[J]. Ther Drug Monit，2008，30(1)：46-51.
[13] SCHAIER M， SCHOLL C， SCHARPF D， et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil[J]. Rheumatology， 2010，49(11)：2061-2067.
[14] VAN GELDER T， PESCOVITZ M， ELZEIN H， et al. The effect of gastric pH modulators on the pharmacokinetics of mycophenolate mofetil (MMF) in de novo renal transplant patients[J]. Presented at the International Congress of the Transplantation Society 2004 [Abstract].
[15] FAN P Y W， BARRACLOUGH K A， ISBEL N M， et al. Impact of omeprazole on mycophenolic acid pharmacokinetics in adult kidney transplant recipients[J]. Presented at the International Congress of the Transplantation Society， 2010 [Abstract].
[16] POOMMIPANIT N B， BUNNAPRADIST S. CNI sparing： short-term results promising， but long-term data needed[J]. Nephrology times， 2009，2(8)：6-10.